InflaRx (NASDAQ:IFRX) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

InflaRx (NASDAQ:IFRX) released its earnings results on Tuesday. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.04, FiscalAI reports.

Here are the key takeaways from InflaRx’s conference call:

• InflaRx sees a $1.5 billion–$2 billion peak-sales opportunity for izicopan in ANCA-associated vasculitis, based on physician market research and potential use in the 70%–80% of patients with renal involvement.
• The company believes izicopan could offer faster onset, higher exposure, lower pill burden, and fewer drug–drug interaction concerns than avacopan; 197 subjects have been dosed to date without reported safety signals of concern, although longer-term data remain limited.
• InflaRx plans two parallel phase II AAV studies: a randomized, placebo-controlled renal vasculitis trial focused on eGFR, proteinuria, hematuria, and remission, and an open-label study designed to test rapid corticosteroid tapering and potential replacement.
• External experts emphasized that AAV remains a serious, frequently relapsing disease with substantial kidney damage, infection risk, and glucocorticoid toxicity, while prior avacopan data support steroid-sparing and renal-function benefits but remain clouded by a retracted publication and ongoing FDA availability questions.
• InflaRx reported EUR 153.3 million in cash and a runway through 2029, with additional programs planned in atypical hemolytic uremic syndrome, IgA nephropathy, and rapidly progressive IgA nephropathy; initial readouts are expected as early as 2027–2028.

InflaRx Trading Down 8.6%

Shares of IFRX opened at $1.48 on Thursday. InflaRx has a 1 year low of $0.80 and a 1 year high of $2.95. The stock has a market cap of $218.11 million, a P/E ratio of -2.55 and a beta of 2.38. The stock’s 50-day moving average price is $1.83 and its two-hundred day moving average price is $1.63.

More InflaRx News

Here are the key news stories impacting InflaRx this week:

• Positive Sentiment: InflaRx plans two Phase 2 AAV trials in 2027, including a study in patients with kidney involvement and an open-label study testing whether izicopan can replace corticosteroids. The company expects initial results in 2028. InflaRx Capital Markets Day announcement
• Positive Sentiment: The company estimates izicopan could reach peak AAV sales of $1.5 billion to $2 billion, while acknowledging that this is a forecast rather than established commercial performance. It also plans studies in aHUS and IgA nephropathy. RTTNews report on izicopan plans
• Positive Sentiment: InflaRx reported €153.3 million in cash, cash equivalents and marketable securities at September 30, which it expects to fund operations and clinical development through 2029. Third-quarter EPS was a loss of $0.02, narrower than analysts’ expected $0.04 loss. Third-quarter earnings report
• Neutral Sentiment: The company also announced an advisory board of experts in vasculitis, nephrology and immune-mediated kidney disease, adding specialist input as it develops the program. Izicopan program and advisory board announcement
• Negative Sentiment: The main AAV trial data are not expected until 2028, and the sales opportunity depends on successful future studies and commercialization. That leaves substantial development and execution risk before the projections can be validated.

Analysts Set New Price Targets

Several equities analysts recently issued reports on IFRX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a report on Monday, September 21st. Zacks Research lowered shares of InflaRx from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 25th. Cantor Fitzgerald raised their price objective on shares of InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Finally, Needham & Company LLC began coverage on shares of InflaRx in a report on Monday, September 14th. They set a “buy” rating and a $8.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.43.

About InflaRx

InflaRx N.V. (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.

The company’s lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a.